Rhythm Biosciences logo

Rhythm Biosciences(ASX) RHY

Market CapA$27.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-73%
5 Year-94%
1 Year-16%
1 Month-9%
A$0.08
+4.17%
+0.00Today
Rhythm Biosciences last closing stock price
MetricPriceDate
Last closeAUD 0.082026-10-09
Rhythm Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.25%AUD 0.082026-10-02
1 month-8.54%AUD 0.082026-09-09
3 month-17.58%AUD 0.092026-07-10
Year to date-44.44%AUD 0.142025-12-31
1 year-15.73%AUD 0.092025-10-09
3 year-75.41%AUD 0.312023-10-10
5 year-93.72%AUD 1.202021-10-08
Since inception-72.99%AUD 0.282017-12-07

Rhythm Biosciences Financials at a Glance

Market Cap

A$27.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$3.28M

Net Income (TTM)

-A$9.76M

EPS (TTM)

-A$0.02

P/E Ratio

-4.24

Dividend

A$0.00

Beta (Volatility)

-0.03 (Low)

Price

A$0.08

Volume

216,340

Open

A$0.07

Previous Close

A$0.08

Daily Range

A$0.07 - A$0.08

52-Week Range

A$0.07 - A$0.28

Estimated Earnings Date

Feb 24, 2027

RHY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rhythm Biosciences

Rhythm Biosciences Limited is a forward-thinking enterprise focused on predictive cancer diagnostics, operating in both Australian and global markets. The company specializes in the development and commercialization of innovative medical diagnostic technologies, with a key product being ColoSTAT, a blood test designed for the early detection of colorectal cancer.

Products and Services
  • ColoSTAT: A specialized blood test for colorectal cancer detection
  • Innovative diagnostic technologies aimed at improving cancer outcomes
  • Research and development in predictive diagnostics
Growth Outlook
  • Significant market potential in cancer diagnostics, projected to grow substantially
  • Expansion plans targeting both domestic and international markets
  • Continued investment in R&D to enhance product offerings and capabilities
Financial Highlights
  • Recent quarterly revenue of 39,092 AUD, showing potential for growth
  • Cash and cash equivalents of 3,355,261 AUD, providing operational stability
  • Current ratio of 3.61, indicating strong liquidity position
Rhythm Biosciences Limited is positioned in the medical diagnostics sector, focusing on innovative solutions for cancer detection. The company's flagship product, ColoSTAT, represents a significant advancement in early cancer diagnosis, which is critical for improving patient outcomes. The growth outlook is promising, with a focus on expanding market reach and enhancing product capabilities through ongoing research and development. Financially, the company has demonstrated resilience with a solid cash position, allowing for continued operations and investment in future growth. The current ratio indicates a strong liquidity position, which is essential for navigating the challenges of the healthcare industry. Overall, Rhythm Biosciences Limited presents an intriguing opportunity for investors interested in the evolving field of medical diagnostics.
AI Generated • Sep 22, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

CEO

David George Atkins, PhD, MBA

Website

www.rhythmbio.com

Headquarters

Parkville, VIC 3010, AU

RHY Financials

Key Financial Metrics (TTM)

Gross Margin

-5151.30%

Operating Margin

-8739.15%

Net Income Margin

-6948.85%

Return on Equity

-205.17%

Return on Capital

-191.96%

Return on Assets

-124.14%

Earnings Yield

-23.58%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$27.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

364.06M

Volume

216.34K

Avg. Volume

220.37K

Financials (TTM)

Gross Profit

-A$4.02M

Operating Income

-A$11.26M

EBITDA

-A$10.80M

Operating Cash Flow

-A$8.15M

Capital Expenditure

-A$49.01K

Free Cash Flow

-A$8.20M

Cash & ST Invst.

A$3.44M

Total Debt

A$247.98K

Rhythm Biosciences Performance Analysis

Rhythm Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 25,126N/A
20262026-06-30AUD 85,339239.6%
Rhythm Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3130.8%
Q42025-06-30-99.2%
Q22025-12-3184.1%
Q42026-06-30-15.5%
Rhythm Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.04-9.5%
20242024-06-30AUD -0.03-19.1%
20252025-06-30AUD -0.01-52.7%
20262026-06-30AUD -0.0224.6%
Rhythm Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31119.7%
Q42025-06-30-778.3%
Q22025-12-3154.5%
Q42026-06-30-49.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$39.09K

-98.4%

Gross Profit

-A$2.26M

-286.4%

Gross Margin

-57.75%

N/A

Market Cap

A$27.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.19M

N/A

Employees

23

N/A

Net Income

-A$3.67M

-32.8%

EBITDA

-A$3.57M

-34.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$3.44M

+356.0%

Total Debt

A$247.98K

+51.4%

Accounts Receivable

A$64.27K

+72.8%

Inventory

A$16.30K

N/A

Long Term Debt

A$75.83K

-11.3%

Short Term Debt

A$172.15K

+119.7%

Return on Assets

-1.24%

N/A

Return on Invested Capital

-2.00%

N/A

Free Cash Flow

-A$3.04M

+1.7%

Operating Cash Flow

-A$3.01M

+2.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IIQ.AXINOVIQ Ltd
A$0.16-3.13%
OSL.AXOncoSil Medical Ltd
A$0.70-1.41%
BDX.AXBCAL Diagnostics Limited
A$0.09+0.00%
NOX.AXNoxopharm Limited
A$0.06-1.61%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About RHY

What is the current price of Rhythm Biosciences?

Rhythm Biosciences is trading at A$0.08 per share.

What is the 52-week range for Rhythm Biosciences?

Over the past 52 weeks, Rhythm Biosciences has traded between A$0.07 and A$0.28.

How much debt does Rhythm Biosciences have?

As of the most recent reporting period, Rhythm Biosciences reported total debt of A$247.98K.

How much cash does Rhythm Biosciences have on hand?

Rhythm Biosciences reported A$3.36M in cash and cash equivalents in its most recent financial results.

What is Rhythm Biosciences’s dividend yield?

Rhythm Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services